The risk of venous thrombosis in women over 50years old using oral contraception or postmenopausal hormone therapy

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 1, 2013, Pages 124-131

  Roach, R E J ^a   Lijfering, W M ^a   Helmerhorst, F M ^a   Cannegieter, S C ^a   Rosendaal, F R ^a   van Hylckama Vlieg, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Oral contraception; Postmenopausal hormone therapy; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; CONJUGATED ESTROGEN; DESOGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROTHROMBIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HORMONAL THERAPY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; VEIN THROMBOSIS;

ADMINISTRATION, CUTANEOUS; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LEVONORGESTREL; LOGISTIC MODELS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NETHERLANDS; NORETHINDRONE; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TRANSDERMAL PATCH; VENOUS THROMBOSIS;

EID: 84873038309     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12060     Document Type: Article

References (34)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-9.
2. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
3. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
4. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-82.
5. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
6. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
7. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-31.
8. Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340-5.
9. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.
10. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.
11. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-300.
12. Hardman SM, Gebbie AE. Hormonal contraceptive regimens in the perimenopause. Maturitas 2009; 63: 204-12.
13. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-5.
14. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovella F, Turpie AG, Middeldorp S, van NP, Prandoni P, Wells PS, Kovacs MJ, MacGillavry MR, Costantini L, Ginsberg JS. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005; 3: 943-8.
15. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581-7.
16. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278-88.
17. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610-5.
18. Rothman KJ. Types of epidemiologic study. Epidemiology: An Introduction. New York: Oxford University Press, 2002; 73-87.
19. Miettinen OS. The "case-control" study: valid selection of subjects. J Chronic Dis 1985; 38: 543-8.
20. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
21. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA 2008; 299: 1306-14.
22. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19, 731 Norwegian women. Am J Epidemiol 2003; 157: 923-9.
23. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR Jr. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511-8.
24. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-44.
25. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 680-90.
26. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-4.
27. Guimaraes DA, dos Santos MS, Gomes KB, van der Bom JG, Rios DR, Cardoso J, Franco RM, Teixeira GS, Dusse LM, Carvalho M, Fernandes AP. Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women. Menopause 2012; 19: 339-45.
28. Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 1012-7.
29. Straczek C, Oger E, Yon de Jonage- Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495-500.
30. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Rosendaal FR, Psaty BM. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol 2006; 26: 2807-12.
31. Canonico M, Oger E, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259-65.
32. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010; 126: 5-11.
33. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
34. Parker AC, Mundada LV, Schmaier AH, Fay WP. Factor V Leiden inhibits fibrinolysis in vivo. Circulation 2004; 110: 3594-8.